OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502):
Underlying Revenue growth of 6.6% led by Takeda's Growth Drivers
Double-digit EPS growth driven by Revenue growth and significant margin gains
Significant progress on Cash Flow and reduced net leverage
James Kehoe, Chief Financial Officer of Takeda, commented:
"Takeda delivered a strong start to the year on both revenue and profitability, driven by the continued strength of our Growth Drivers and good progress on our cost management initiatives. We are executing well against our key priorities of growing the portfolio, rebuilding the pipeline, and boosting profitability, and the first quarter results confirm our confidence in the full-year outlook for double-digit EPS growth."
Reported Results for Q1 (April - June) FY2017
|(billion yen)||FY2016 Q1||FY2017 Q1||Growth|
|EPS||127 yen||186 yen||+45.8%||-|
|Core EPS||71 yen||103 yen||+44.5%||+35.7%|
|1||Core Earnings is calculated by taking reported Gross Profit and deducting SG&A expenses and R&D expenses. In addition, certain other items that are non-core in nature and significant in value may also be adjusted.|
|2||Underlying growth compares two periods of financial results on a common basis, showing the ongoing performance of the business excluding the impact of foreign exchange and divestitures from both periods.|
|3||Attributable to the owners of the company.|
Takeda maintains its Management Guidance and Reported Forecast for FY2017, projecting double-digit EPS growth.
FY2017 Management Guidance
|Guidance (growth %)|
|Underlying Revenue||Low single digit|
|Underlying Core Earnings||Mid-to-high teen|
|Underlying Core EPS||Low-to-mid teen|
|Annual dividend per share||180 yen|
FY2017 Reported Forecast
|(billion yen)||FY2016 Results||FY2017 Forecast||% change|
|EPS||147 yen||177 yen||+20.1%|
|1 US$= 109 yen
1 euro= 120 yen
|1 US$= 110 yen
1 euro= 120 yen
For more details on Takeda’s FY2017 first quarter results and other financial information please visit https://www.takeda.com/investors/reports/
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in Emerging Markets, are currently fueling the growth of Takeda. Around 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/.